Immune checkpoint inhibitors are antibodies that block the interaction of CTLA-4 or PD-1 with their ligands and cause the reinvigoration of exhausted T cells leading to long-term favorable responses in a small percentage of cancer patients [8]. The gene discussed is PDCD1; the disease is cancer.